Fdg-pet and pet/ct in the clinical management of gastrointestinal stromal tumor

Nuclear Medicine Communications

Volumn 29, Issue 12, 2008, Pages 1026-1039

  Basu, Sandip ^a   Mohandas, Kunissery Mallath ^a   Peshwe, Harish ^a   Asopa, Ramesh ^a   Vyawahare, Manoj ^a  

^a TATA MEMORIAL HOSPITAL   (India)

Author keywords

Gastroenterology; Gastrointestinal stromal tumor; PET; PET computed tomography; Stromal tumor

Indexed keywords

FLUORODEOXYGLUCOSE F 18; IMATINIB; PROTEIN KINASE INHIBITOR;

COMPUTER ASSISTED TOMOGRAPHY; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DISEASE ACTIVITY; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG UPTAKE; DRUG WITHDRAWAL; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERMETHOD COMPARISON; MALIGNANT TRANSFORMATION; OPTIMAL DRUG DOSE; PATIENT MONITORING; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; PROGRESSION FREE SURVIVAL; REVIEW; TREATMENT RESPONSE; TUMOR DIAGNOSIS; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; FLUORODEOXYGLUCOSE F18; GASTROINTESTINAL STROMAL TUMORS; HUMANS; MALE; MIDDLE AGED; PIPERAZINES; POSITRON-EMISSION TOMOGRAPHY; PYRIMIDINES; TOMOGRAPHY, X-RAY COMPUTED;

EID: 56749156278     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/MNM.0b013e328313bbe7     Document Type: Review

References (38)

1. Miettinen M, Lasota J. Gastrointestinal stromal tumors—definition, clinical, histological, immunohistochemical, and molecular genetic features and differential diagnosis. Virchows Arch 2001; 438:1-12.
2. Emory TS, Sobin LH, Lukes L, Lee DH, O’Leary TJ. Prognosis of gastrointestinal smooth-muscle (stromal) tumors: dependence on anatomic site. Am J Surg Pathol 1999; 23:82-87.
3. Berman J, O’Leary TJ. Gastrointestinal stromal tumor workshop. Hum Pathol 2001; 32:578-582.
4. Appelman HD. Mesenchymal tumors of the gut: histological perspectives, new approaches, new results, and does it make any difference. Monogr Pathol 1990; 31:220-246.
5. Demetri GD, von Mehren M, Blanke CD, Van den Abbeele AD, Eisenberg B, Roberts PJ, et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. N Engl J Med 2002; 347:472-480.
6. Chen MY, Bechtold RE, Savage PD. Cystic changes in hepatic metastases from gastrointestinal stromal tumors (GISTs) treated with Gleevec (imatinib mesylate). Am J Roentgenol 2002; 179:1059-1062.
7. Joensuu H, Fletcher C, Dimitrijevic S, Silberman S, Roberts P, Demetri G. Management of malignant gastrointestinal stromal tumours. Lancet Oncol 2002; 3:655-664.
8. Van den Abbeele AD, Badawi RD. Use of positron emission tomography in oncology and its potential role to assess response to imatinib mesylate therapy in gastrointestinal stromal tumors (GISTs). Eur J Cancer 2002; 38 (Suppl 5):S60-S65.
9. Stroobants S, Goeminne J, Seegers M, Dimitrijevic S, Dupont P, Nuyts J, et al. 18FDG-positron emission tomography for the early prediction of response in advanced soft tissue sarcoma treated with imatinib mesylate (Glivec). Eur J Cancer 2003; 39:2012-2020.
10. Gayed I, Vu T, Iyer R, Johnson M, Macapinlac H, Swanston N, Podoloff D. The role of 18F-FDG PET in staging and early prediction of response to therapy of recurrent gastrointestinal stromal tumors. J Nucl Med 2004; 45:17-21.
11. Antoch G, Kanja J, Bauer S, Kuehl H, Renzing-Koehler K, Schuette J, et al. Comparison of PET, CT, and dual-modality PET/CT imaging for monitoring of imatinib (STI571) therapy in patients with gastrointestinal stromal tumors. J Nucl Med 2004; 45:357-365.
12. Goerres GW, Stupp R, Barghouth G, Hany TF, Pestalozzi B, Dizendorf E, et al. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate. Eur J Nucl Med Mol Imaging 2005; 32:153-162.
13. Jager PL, Gietema JA, van der Graaf WT. Imatinib mesylate for the treatment of gastrointestinal stromal tumours: best monitored with FDG PET. Nucl Med Commun 2004; 25:433-438.
14. Gelibter A, Milella M, Ceribelli A, Zeuli M, Ferraresi V, Vecchione A, Cognetti F. PET scanning evaluation of response to imatinib mesylate therapy in gastrointestinal stromal tumor (GIST) patients. Anticancer Res 2004; 24:3147-3151.
15. Goldstein D, Tan BS, Rossleigh M, Haindl W, Walker B, Dixon J. Gastrointestinal stromal tumours: correlation of F-FDG gamma camera-based coincidence positron emission tomography with CT for the assessment of treatment response - an AGITG study. Oncology 2005; 69:326-332.
16. Heinicke T, Wardelmann E, Sauerbruch T, Tschampa HJ, Glasmacher A, Palmedo H. Very early detection of response to imatinib mesylate therapy of gastrointestinal stromal tumours using 18fluoro-deoxyglucose-positron emission tomography. Anticancer Res 2005; 25:4591-4594.
17. Goh BK, Chow PK, Chuah KL, Yap WM, Wong WK. Pathologic, radiologic and PET scan response of gastrointestinal stromal tumors after neoadjuvant treatment with imatinib mesylate. Eur J Surg Oncol 2006; 32:961-963. Epub 2006 Jul 12.
18. Choi H, Charnsangavej C, Faria SC, Macapinlac HA, Burgess MA, Patel SR, et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol 2007; 25:1753-1759.
19. Holdsworth CH, Badawi RD, Manola JB, Kijewski MF, Israel DA, Demetri GD, Van den Abbeele AD. CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. AJR Am J Roentgenol 2007; 189:W324-W330.
20. Joensuu H. Treatment of inoperable gastrointestinal stromal tumor (GIST) with imatinib (Glivec, Gleevec). Med Klin (Munich)2002; 97 (Suppl 1):28-30.
21. Basu S, Nair N, Peshwe H, Mohandas KM. Potential role of FDG-PET to assess response to imatinib mesylate therapy and detecting viable disease in gastrointestinal stromal tumors (GIST). J Nucl. Med 2004; 45 (Suppl):89P.
22. Sevinc A, Camci C, Yilmaz M, Buyukhatipoglu H. The diagnosis of C-Kit negative GIST by PDGFRA staining: clinical, pathological, and nuclear medicine perspective. Onkologie 2007; 30:645-648.
23. Kamiyama Y, Aihara R, Nakabayashi T, Mochiki E, Asao T, Kuwano H, et al. 18F-fluorodeoxyglucose positron emission tomography: useful technique for predicting malignant potential of gastrointestinal stromal tumors. World J Surg 2005; 29:1429-1435.
24. Yamada M, Niwa Y, Matsuura T, Miyahara R, Ohashi A, Maeda O, et al. Gastric GIST malignancy evaluated by 18FDG-PET as compared with EUS-FNA and endoscopic biopsy. Scand J Gastroenterol 2007; 42:633-641.
25. Hersh MR, Choi J, Garrett C, Clark R. Imaging gastrointestinal stromal tumors. Cancer Control 2005; 12:111-115.
26. Tamborini E, Pricl S, Negri T, Lagonigro MS, Miselli F, Greco A, et al. Functional analyses and molecular modeling of two c-Kit mutations responsible for imatinib secondary resistance in GIST patients. Oncogene 2006; 25:6140-6146. Epub 2006 Jun 5.
27. von Mehren M. Imatinib-refractory gastrointestinal stromal tumors: the clinical problem and therapeutic strategies. Curr Oncol Rep 2006; 8:192-197.
28. Kövér E, Faluhelyi Z, Bogner B, Kalmár K, Horváth G, Tornóczky T. Dual tumours in the GI tract: synchronous and metachronous stromal (GIST) and epithelial/neuroendocrine neoplasms. Magy Onkol 2004; 48:315-321. [Epub 2005 Jan 17].
29. Kalmár K, Tornóczky T, Pótó L, Illényi L, Kalmár Nagy K, Kassai M, et al. Gastrointestinal stromal tumours in a single institute: is there an association to other gastrointestinal malignancies? Magy Seb 2004; 57:251-256.
30. Lamba M, Verma S, Prokopetz R, Pierscianowski TA, Jabi M, Moyana T. Multiple cutaneous and uterine leiomyomas associated with gastric GIST. J Cutan Med Surg 2005; 9:332-335.
31. Knop S, Schupp M, Wardelmann E, Stueker D, Horger MS, Kanz L, et al. New case of Carney triad: gastrointestinal stromal tumours and leiomyoma of the oesophagus do not show activating mutations of KIT and platelet-derived growth factor receptor alpha. J Clin Pathol 2006; 59:1097-1099.
32. Zachäus M, Plötner A, Weimann A, Ruf B. Multiple gastrointestinal stromal tumors in neurofibromatosis type 1. Med Klin (Munich) 2007; 102:163-167.
33. Alam I, Frahad K, Griffiths PA, Hurley M. Simultaneous gastrointestinal stromal tumor and mucosa-associated lymphoid tissue lymphoma of the stomach. J Clin Oncol 2007; 25:1136-1138.
34. Salar A, Ramon JM, Barranco C, Nieto M, Prats M, Serrano S, Besses C. Synchronous mucosa-associated lymphoid tissue lymphoma and gastrointestinal stromal tumors of the stomach. J Clin Oncol 2005; 23:7221-7223.
35. Basu S, Nair N, Mohandas KM. FDG-avid thyroid incidentaloma in advanced gastrointestinal stromal tumor: metachronous dual primaries. Indian J Gastroenterol 2007; 26:146-147.
36. Agaimy A, Pelz AF, Corless CL, Wünsch PH, Heinrich MC, Hofstaedter F, et al. Schneider-Stock R. Epithelioid gastric stromal tumours of the antrum in young females with the Carney triad: a report of three new cases with mutational analysis and comparative genomic hybridization. Oncol Rep 2007; 18:9-15.
37. Efstathios P, Athanasios P, Papaconstantinou I, Alexandros P, Frangisca S, Sotirios G, et al. Coexistence of gastrointestinal stromal tumor (GIST) and colorectal adenocarcinoma: a case report. World J Surg Oncol 2007; 21:5-96.
38. Kalender ME, Sevinc A, Kucukdurmaz Z, Balik A, Sari I, Camci C. Gastric and prostate adenocarcinoma in a patient with metastatic gastrointestinal stromal tumor. Onkologie 2007; 30:568-570. [Epub 2007 Oct 5].